GlassScriptPhysician profile
Amanda Marie Denney
NPI 1003871047
$183,184.66
in general payments reported to CMS, 2019-2025
34 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $30K · 2021: $23K · 2022: $30K · 2023: $13K · 2024: $13K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $6,340 · Food and Beverage: $4,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,462.50 |
| Travel and Lodging | $6,339.94 |
| Food and Beverage | $4,702.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101,795.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $44,483.77 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,519.72 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $830.54 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Astrazeneca Pharmaceuticals LP | $612.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $512.40 | 2019-2025 | |
| Insulet Corporation | $395.46 | 2019-2025 | Omnipod |
| Amgen INC. | $176.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $172.54 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $151.76 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Boston Scientific Corporation | $145.12 | 2024 | Wavewriter Alpha Prime 16 |
| Beta Bionics, INC. | $139.12 | 2023 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $137.65 | 2019-2025 | Korlym |
| Sequel Med Tech, LLC | $137.55 | 2025 | Twiist |
| Abbott Laboratories | $103.67 | 2019-2023 | Freestyle Libre, Freestyle Libre 2 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $102.08 | 2019 | |
| Abbvie INC. | $93.11 | 2019-2023 | Synthroid |
| Shire North American Group INC | $84.82 | 2019 | |
| Tandem Diabetes Care, INC. | $81.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $76.89 | 2019-2020 | |
| Pfizer INC. | $57.81 | 2024 | |
| Mannkind Corporation | $45.33 | 2019 | |
| Merck Sharp & Dohme LLC | $41.92 | 2019 | |
| Amryt Pharma Holdings LTD | $41.25 | 2022 | |
| Valeritas, INC. | $38.40 | 2019 | |
| Vivus LLC | $35.25 | 2019 | |
| Lifescan, INC. | $33.30 | 2019 | |
| Amarin Pharma, INC. | $26.40 | 2019 | |
| Currax Pharmaceuticals LLC | $26.04 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.74 | 2023 | Strensiq |
| Radius Health, INC. | $18.03 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $15.76 | 2019 | |
| Senseonics, Incorporated | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.